Localization of the components of the plasminogen activation system in cutaneous melanocytic lesions - A minireview

Fibrinolysis

Volumn 10, Issue SUPPL. 2, 1996, Pages 91-94

  De Vries, T J ^a   Ruiter, D J ^a   Weidle, U H ^b   Van Muijen, G N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN; PLASMINOGEN ACTIVATOR;

CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; SKIN TUMOR;

EID: 0029904108     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80058-0     Document Type: Conference Paper

References (21)

1. De Vries TJ, Van Muijen GNP, Ruiter DJ. The plasminogen activation system in tumour invasion and metastasis. In: Pathology Update, Vol 3, 1996. (Ed. F. Bosman), Fisher Verlag. In press.
2. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
3. De Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GNP. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994; 144: 70-81.
4. Delbaldo C, Masouye I, Saurai J-H, Vassalli J-D, Sappino A-P. Plasminogen activation in melanocytic neoplasia. Cancer Res 1994; 54: 4547-4552.
5. 2-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res 1996; 56: 1432-1439.
6. De Vries TJ, De Wit PEJ, Clemmensen I, Verspaget HW, Weidle UH, Bröcker EB, Ruiter DJ, Van Muijen GNP. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. J Pathol 1996, in press.
7. De Vries TJ, Van Muijen GNP, Ruiter DJ. The plasminogen activation system in melanoma cell lines and in melanocytic lesions - a review. Melanoma Res 1996; 6, 79-88.
8. Häffner AC, Garbe C, Burg G, Büttner P, Orfanos CE, Rassner G. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 1992; 66: 856-861.
9. Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993; 71: 3737-3743.
10. Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75: 2484-2491.
11. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041.
12. Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluids and its conditioning for use in vivo. Thromb Haemost 1982; 48: 294-296.
13. Kwaan HC, Radosevich JA, Xu CG, Lastre C. Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma. Tumor Biol 1988; 9: 301-306.
14. Wojtukiewitcz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-521.
15. Markus G, Kohga S, Camiolo SM, Madeja JM, Ambrus JL, Karakousis C. Plasminogen activators in human malignant melanoma. J Nat Cancer Inst 1984; 72: 1213-1222.
16. De Vries TJ, Mooy CM, Van Balken MR, Luyten GPM, Quax PHA, Verspaget HW, Weidle UH, Ruiter DJ, and Van Muijen GNP. Components of the plasminogen activation system in uveal melanoma - a clinico-pathological study. J Pathol 1995; 175: 59-67.
17. De Vries TJ, Kitson JL, Silvers WK, Mintz B: Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma susceptible mice. Cancer Res 1995; 55: 4681-4687.
18. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986; 156: 327-333.
19. Christensen L, Clemmensen I. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 1991; 95: 427-433.
20. Verspaget HW, Clemmensen I, Ganesh S, Christensen L, Sier CFM, Griffioen G, Lamers CBHW. Tetranectin expression in human colonic neoplasia. Histopathology 1994; 25: 463-467.
21. Andreasen PA, Sottrup-Jensen L, Kjøller L, Nykjær A, Moestrup SK, Petersen CM, Gliemann J. Receptor mediated endocytosis of plasminogen activator/inhibitor complexes. FEBS Letters 1994; 338: 239-245.